Association of Mixed Lineage Kinase Domain-Like Protein Expression With Prognosis in Patients With Colon Cancer
Association of Mixed Lineage Kinase Domain-Like Protein Expression With Prognosis in Patients With Colon Cancer
复制标题
DOI：
10.1177/1533034616655909
复制
发表时间：
2017-08-01
影响因子：
2.8
通讯作者：
Sun, Zhen-Qing
中科院分区：
文献类型：
--
作者：
Li, Xian;Guo, Jing;Sun, Zhen-Qing
背景资料：混合谱系激酶结构域样蛋白最近被鉴定为肿瘤坏死因子诱导的坏死性凋亡的关键下游组分，坏死性凋亡是癌细胞死亡的重要途径。本研究旨在探讨混合谱系激酶结构域样蛋白在结肠癌组织中的表达及其对结肠癌患者预后的价值。研究方法：收集2007年7月至2009年4月青岛大学附属医院收治的135例结肠癌根治术后患者的正常结肠组织和癌组织。使用已建立的评分系统对免疫组织化学分析进行评分。生成所有患者和2个患者亚组的无复发生存期和总生存期的Kaplan-Meier生存曲线。采用单因素和多因素考克斯回归分析混合谱系激酶结构域样蛋白表达与预后参数（无复发生存期、总生存期）的关系。结果：所有患者的中位年龄为67岁，56.3%为男性。在所有患者中，混合谱系激酶结构域样蛋白的低表达与总生存期降低相关（78.6 vs 81.2个月; P = 0.011）。在接受辅助化疗的79例患者中，混合谱系激酶结构域样蛋白的低表达与无复发生存期（60.4 vs 72.8个月; P = 0.032）和总生存期（66.3 vs 72.9个月; P = 0.005）降低相关。混合谱系激酶结构域样蛋白的低表达与肿瘤淋巴结转移（TNM）II期结肠癌患者的总生存期（4.9 vs 79.8个月; P = 0.006）和无复发生存期（69.6 vs 78.8个月; P = 0.005）降低相关。结论：混合谱系激酶结构域样蛋白的低表达与所有切除的结肠癌患者组的总生存率降低相关。在接受辅助化疗的患者和TNM分期II的患者中，它与降低无复发生存率和总生存率相关。混合谱系激酶结构域样蛋白可能为结肠癌患者提供重要的预后信息。
Background: The mixed lineage kinase domain-like protein has recently been identified as a key downstream component of tumor necrosis factor-induced necroptosis, which is an important pathway of cancer cell death. The goal of the current study is to explore the expression of mixed lineage kinase domain-like protein in colon cancer tissues and evaluate the prognostic value in patients with colon cancer. Methods: We collected normal and cancer colon tissues from 135 patients diagnosed with colon cancer after radical operation during July 2007 to April 2009 at The Affiliated Hospital of Qingdao University. Immunohistochemistry analysis was scored using an established scoring system. Kaplan-Meier survival curves were generated for recurrence-free survival and overall survival for all patients and 2 subsets of patients. The relationship between mixed lineage kinase domain-like protein expression and prognosis parameter (recurrence-free survival, overall survival) was analyzed by univariate and multivariate Cox regression analyses. Results: The median age of all patients was 67 years and 56.3% were male. Low expression of mixed lineage kinase domain-like protein was associated with decreased overall survival (78.6 vs 81.2 months; P = .011) in all patients. In the subset of 79 patients who received adjuvant chemotherapy, low expression of mixed lineage kinase domain-like protein was associated with decreased recurrence-free survival 60.4 vs 72.8 months; P = .032) and decreased overall survival ( 66.3 vs 72.9 months; P = .005). Low expression of mixed lineage kinase domain-like protein was associated with decreased overall survival (4.9 vs 79.8 months; P = .006) and recurrence-free survival (69.6 vs 78.8 months; P = .005) among patients with Tumor Node Metastasis (TNM) stage II colon cancer. Conclusions: Low expression of mixed lineage kinase domain-like protein was associated with decreased overall survival in all patient-group with resected colon cancer. It is associated with decreased recurrencefree survival and overall survival in the subset of patients who receive adjuvant chemotherapy and patients who were TNM stage II. Mixed lineage kinase domain-like protein may provide important prognostic information in patients with colon cancer.